Early Day Notes: CytRx Corporation (NASDAQ:CYTR), MannKind Corp. (NASDAQ:MNKD), Protalix BioTherapeutics (NYSEMKT:PLX), KaloBios Pharmaceuticals (NASDAQ:KBIO)

Posted by on Nov 25, 2015

Lion Biotechnologies, Inc. (NASDAQ:LBIO) shares advanced 3.46% in last trading session and ended the day at $6.58. LBIO has a return on assets of -30.40%. Lion Biotechnologies, Inc. (NASDAQ:LBIO) quarterly performance is 4.11%.

Lion Biotechnologies, (NASDAQ:LBIO), announced that President and CEO Elma Hawkins, PhD, will participate in the Piper Jaffray 27th Annual Healthcare Conference 1-2 December, 2015 and Roth Immuno-Oncology Corporate Access Day on 16 December, 2015.

CytRx Corporation (NASDAQ:CYTR) ended the last trading day at $3.06. Company weekly volatility is calculated as 4.80% and price to cash ratio as 2.87. CytRx Corporation (NASDAQ:CYTR) showed a weekly performance of -0.65%.

CytRx Corporation (NASDAQ:CYTR), announced that it has achieved its target enrollment of 28 patients with unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer, in its Phase 2 trial with aldoxorubicin. To date, aldoxorubicin has shown evidence of tumor shrinkage, and overall survival has not yet been reached. Additionally, an advisory board of neuro-oncologists recently met to review the updated Phase 2 results and concluded that aldoxorubicin should be evaluated in combination with AvastinĀ® in what could potentially be a pivotal trial in patients with late-stage GBM.

On 24 November, MannKind Corp. (NASDAQ:MNKD) shares moved down -2.22% and was closed at $2.20. MNKD EPS growth in last 5 year was 24.40%. MannKind Corp. (NASDAQ:MNKD) year to date (YTD) performance is -57.81%.

MannKind Corporation (NASDAQ:MNKD) and (MNKD.TA) announced that Hakan Edstrom has stepped down as the President, Chief Executive Officer and as a director of MannKind. The board of directors of MannKind appointed Alfred Mann as interim Chief Executive Officer, effective November 19, 2015. Mr. Mann will continue to serve as the Executive Chairman of the Company. A committee of the board will commence an immediate search for a successor CEO.

Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) shares advanced 4.90% in last trading session and ended the day at $1.07. Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) quarterly performance is -23.02%.

On 16 November, Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced that it recently held an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s proposed BLA plan for PRX-102 for the treatment of Fabry disease. Official FDA meeting minutes indicate the FDA’s acceptance of the Company’s path forward for a phase III clinical trial to support a full BLA approval.

KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) caters to the Healthcare space. Its weekly performance is 747.93%. On the last day of trading company shares ended up at $18.40. KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) distance from 50-day simple moving average (SMA50) is -0.29%.

On 19 November. KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said that Martin Shkreli, founder and head of Turing Pharmaceuticals AG, has become its chief executive after he led an investor group that has purchased a 70% stake in the company. Shkreli stirred controversy in recent weeks by acquiring a drug used to treat parasitic infection and immediately hiking the price.

Leave a Reply

Your email address will not be published. Required fields are marked *